Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

Fig. 3

ROC curves for MET, Ki-67, PTEN, and MET combined with Ki-67 parameters. Parameters plotted include: MET/CEN7 gain or loss (solid line with solid triangles; repeated from Fig. 2), Ki-67 expression (dotted line with solid diamonds), PTEN gain (long dashed line with solid circles), and MET/CEN7 gain or loss held at a constant cutoff of 50 % of cells while varying the cutoff for Ki-67 expression (short dashed line with solid squares)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us